## EXE: Expand Energy Corporation - XLE: Energy

### Executive Summary

No thesis match: MRS_20 -4.7% below STRENGTH zone (4.0-10.0%); PEG 1.56 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($105.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. How Is Coterra Energy's Stock Performance Compared to Other Oil & Gas E&P Stocks?**
- Source: inkl | 20251210T150735 | Somewhat-Bullish | Relevance: 62%
- Coterra Energy Inc. (CTRA) is a large-cap independent oil and gas company whose stock has outperformed the iShares U.S. Oil & Gas Exploration & Production ETF (IEO) over the past three months and 52 weeks, but slightly lagged IEO year-to-date. Despite underperforming some rivals like Expand Energy Corporation (EXE), analysts maintain a "Strong Buy" rating for CTRA with a significant upside potential based on their mean price target. The company's Q3 2025 results, which included strong production and reaffirmed free cash flow guidance, contributed to a nearly 6% stock climb.

**2. Should ConocoPhillipsâ€™ Raised Output and Lower Costs in Q3 2025 Require Action From COP Investors?**
- Source: Simply Wall Street | 20251214T202507 | Neutral | Relevance: 58%
- ConocoPhillips exceeded analyst expectations in Q3 2025, increasing full-year production guidance and lowering operating cost guidance, indicating strong operational performance. Despite industry-wide supply risks, the company also improved Delaware Basin well productivity. This positive report suggests ConocoPhillips is maximizing output, sharpening its investment narrative around its U.S. shale scale and LNG exposure, though potential oversupply issues remain a key risk for investors.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | UBS | $154 | $132 | +17% |
| 2025-12-12 | Mizuho | $142 | $136 | +4% |
| 2025-11-18 | Piper Sandler | $138 | $136 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | UBS | main | Buy |
| 2025-12-12 | Mizuho | main | Outperform |
| 2025-11-18 | Piper Sandler | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.7% (+2.4%)
- Blackrock Inc.: 8.6% (+4.2%)
- Capital Research Glo: 6.7% (+161.5%)
- State Street Corpora: 5.5% (+8.3%)
- Price (T.Rowe) Assoc: 4.6% (-10.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +8%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.56 elevated, pricing in significant growth expectations. Forward P/E 11.8x attractive for 63% earnings growth. Analyst sentiment positive (3 raises, avg +8%). Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.9B |
| Beta | 0.44 |
| 52W Range | $91.02 - $126.62 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.56 |
| Forward P/E | 11.8 |
| Current P/E | 19.3 |
| YoY Growth | 62.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -1.4% to -4.7% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). AM_20 at -4.4% indicates price below own 20MA trend. Underperforming sector by 4.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-1.21), momentum weakening. RSI neutral at 44. OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.73% (CS: 8) | Weak |
| RSI_14 | 43.7 | Neutral |
| MACD Histogram | -1.21 | Bearish |
| vs SMA20 | 0.956x | Below |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $112.79
- **Stop Loss:** $105.43 (6.5% risk)
- **Target:** $120.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 135
- **Position Value:** $15,226.65
- **Portfolio %:** 15.23%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-24 (Est: $1.58)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.97 | +14.2% |
| 2025Q2 | $1.15 | $1.10 | -4.1% |
| 2025Q1 | $1.87 | $2.02 | +8.0% |
| 2024Q4 | $0.47 | $0.55 | +17.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*